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The efficacy and safety of vitamin K antagonist (VKA) therapy are closely associated to the quality of 
oral anticoagulation (OAC) management, as reflected by the average percentage of the time in therapeutic 
range (TTR). A high TTR translates into a lower risk of stroke and bleeding. Thus, guidelines recommend 
an average individual TTR >65–70%. The SAMeTT2R2 is a clinical risk score developed to predict the 
quality of OAC with VKA, patients with SAME-TT2R2 score ≥2 being at high risk of having poor 
quality on OAC whilst on VKAs. We explore the predictive role of the SAME-TT2R2 score for assessing 
poor anticoagulant control in a prospective cohort of patients on VKA treatment. 
 
Methods: We studied VKA treated non-valvular AF patients who were prospectively recruited in the 
multicentre Spanish observational registry FANTASIIA. Estimated TTR was calculated from both direct 
and Rosendaal methods during a 6 month period. The SAME-TT2R2 score was calculated and TTR 
values compared for those patients with a SAME-TT2R2 score 0–1 and ≥2. 
 
Results: We studied 948 patients (mean age 73.8 ± 9.4 years, 57.5% male). Mean TTR was 63.8 ± 23.8 
for the direct method and 60.3 ± 24.5 for the Rosendaal method. Prevalence of poor anticoagulation 
control (TTR<65%) was 54%. As expected a progressive reduction of TTR was found as SAME-TT2R2 
score values increased (Table). Those patients with SAME-TT2R2 score 0–1 had better mean TTR as 
calculated by the Rosendaal method (62.5 ± 24.7 vs 58.0 ± 24.1; p<0.01).  
Mean TTR for each SAMeTT2R2 value 
SAMeTT2R2 score  N TTR direct TTR Rosendaal 
    
0  159 65.4 ± 22.5 63.2 ± 24.6 
1  387 64.6 ± 23.7 61.5 ± 24.7 
2 289 63.0 ± 25.1 58.3 ± 24.8 
3  84 61.9 ± 23.7 58.4 ± 23.2 
4  25 57.3 ± 18.1 52.1 ± 19.3 
5 4 54.7 ± 21.0 61.1 ± 20.4 
    
 
  
Conclusions: In a multicenter prospective registry, a high SAME-TT2R2 score (≥2 points) is associated 
with poor quality anticoagulation in patients on VKA. Our registry demonstrates the potential role of this 
simple clinical risk score to predict the poor quality OAC with VKA in clinical practice, and helps 
decision making for additional strategies including use of the Non-VKA Oral Anticoagulants. 
 
 
